P. Santabárbara

8.5k total citations · 3 hit papers
33 papers, 6.7k citations indexed

About

P. Santabárbara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, P. Santabárbara has authored 33 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in P. Santabárbara's work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). P. Santabárbara is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). P. Santabárbara collaborates with scholars based in United States, Spain and Canada. P. Santabárbara's co-authors include Gary M. Clark, Lesley Seymour, Frances A. Shepherd, Andrea Bezjak, Dongsheng Tu, Michael Smylie, Sumitra Thongprasert, Mircea Dediu, D. Johnston and Daniel de Castro and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

P. Santabárbara

33 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Frances A. Shepherd, José Rodrigues Pereira et al. New England Journal of Medicine profile →
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 893 citations Eric K. Rowinsky, Gary M. Clark et al. Journal of Clinical Oncology profile →
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

2002 707 citations Ian W. Flinn, Lee Brettman et al. Blood profile →

Peers

Countries citing papers authored by P. Santabárbara

Since Specialization

Citations

This map shows the geographic impact of P. Santabárbara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Santabárbara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Santabárbara more than expected).

Fields of papers citing papers by P. Santabárbara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Santabárbara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Santabárbara. The network helps show where P. Santabárbara may publish in the future.

Co-authorship network of co-authors of P. Santabárbara

This figure shows the co-authorship network connecting the top 25 collaborators of P. Santabárbara. A scholar is included among the top collaborators of P. Santabárbara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Santabárbara. P. Santabárbara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma 2016 ·Blood ·Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna, (unknown), Sarit Assouline, Pier Luigi Zinzani, Jiřı́ Mayer, Michele Merli, Scott D. Lunin, Andrew R. Pettitt, Zsolt Nagy, (unknown), Karim Abou-Nassar, Michael Crump, Eric D. Jacobsen, Sven de Vos, P. Santabárbara, Weiliang Shi, Lori Steelman, Nina D. Wagner‐Johnston	18
2	Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval 2010 ·Annals of Oncology ·Stuart Kaye, Nicoletta Colombo, B.J. Monk, Sergei Tjulandin, Beihua Kong, Moni Roy, Stephen Chan, (unknown), Hans Hagberg, Ignace Vergote, Claudia Lebedinsky, Trilok Parekh, P. Santabárbara, (unknown), Antonio Nieto, Andrés Poveda	47
3	Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). 2010 ·Journal of Clinical Oncology ·Ignacio Romero, N. Colombo, Stuart Kaye, José Ángel Arranz, A. Roszak, Diane Provencher, P. Santabárbara, Eliel Bayever, (unknown), Franco M. Muggia	4
4	Mapping the literature: Role of trabectedin as a new chemotherapyoption in advanced pretreated soft tissue sarcoma 2009 ·Drugs of today ·Axel Le Cesne, Julien Dômont, Angela Cioffi, Sylvie Bonvalot, (unknown), I. L. Ray-Coquard, Vicente Alfaro, Claudia Lebedinsky, P. Santabárbara, Jean‐Yves Blay	12
5	8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older 2009 ·European Journal of Cancer Supplements ·I. Vergote, Jan B. Vermorken, Éric Pujade-Lauraine, B.J. Monk, Alla Lisyanskaya, Janusz Rolski, S. Vasanthan, P. Santabárbara, Eliel Bayever, Andrés Poveda	7
6	Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer 2007 ·Annals of Oncology ·Emiliano Calvo, (unknown), Lillian L. Siu, Gwen Baillargeon, Jonathan Irish, (unknown), P. Santabárbara, Jeffrey I. Kreisberg, Eric K. Rowinsky, Manuel Hidalgo	27
7	7512 POSTER Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens 2007 ·European Journal of Cancer Supplements ·Axel Le Cesne, Margaret von Mehren, (unknown), Jean‐Yves Blay, Scott M. Schuetze, Antonio Nieto, (unknown), P. Santabárbara, Miguel Izquierdo, George D. Demetri	3
8	Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21 2006 ·Clinical Lung Cancer ·Gary M. Clark, (unknown), P. Santabárbara, Keyue Ding, Marlo Whitehead, Lesley Seymour, Frances A. Shepherd	140
9	Erlotinib in Previously Treated Non–Small-Cell Lung Cancer breakdown → 2005 ·New England Journal of Medicine ·Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, (unknown), Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour	4281
10	P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers? 2005 ·Lung Cancer ·Gary M. Clark, Pablo J. Cagnoni, Mieke Ptaszynski, Marta Hamilton, P. Santabárbara, Janna Christy‐Bittel, Bernhard Geiger, Sharon McCarthy, N Onetto	2
11	Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H 2002 ·Leukemia ·(unknown), George H. Shaw, (unknown), (unknown), (unknown), P. Santabárbara, Lee Brettman	16
12	Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. 2001 ·PubMed ·David S. Alberts, Alton V. Hallum, (unknown), Dava J. Garcia, Mary Gleason-Guzman, Sydney E. Salmon, P. Santabárbara, Eric J. Niesor, (unknown), C. Bentzen	28
13	A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. 1999 ·PubMed ·Miguel A. Villalona‐Calero, Thierry Petit, John G. Kuhn, Patrick Cobb, Maura A. Kraynak, Sabine Eckhardt, Ronald Drengler, Cameron P. Simmons, P. Santabárbara, Daniel D. Von Hoff, (unknown)	2
14	A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration 1995 ·Cancer Chemotherapy and Pharmacology ·Mark J. McKeage, Prakash Mistry, Janet Ward, Frances Boxall, (unknown), (unknown), Peter Ellis, Lloyd R. Kèlland, Sarah E. Morgan, Barry A. Murrer, P. Santabárbara, Kenneth R. Harrap, Ian Judson	84
15	A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration 1995 ·Cancer Chemotherapy and Pharmacology ·Mark J. McKeage, Prakash Mistry, Janet Ward, Frances Boxall, (unknown), (unknown), Peter Ellis, Lloyd R. Kèlland, Sarah E. Morgan, Barry A. Murrer, P. Santabárbara, Kenneth R. Harrap, Ian Judson	2
16	Phase II Trial of Cisplatin and Etoposide as First-Line Therapy in Metastatic Breast Carcinoma 1994 ·Oncology ·Aňa Lluch, (unknown), Andrés Cervantes, Montserrat Muñoz-Mateu, V. Alberola, P. Santabárbara, J Garcı́a-Conde	9
17	Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. 1994 ·Journal of Clinical Oncology ·(unknown), Aňa Lluch, Antonio Casado, P. Santabárbara, Encarna Adrover, (unknown), José A. López-Martín, (unknown), (unknown), J Garcı́a-Conde	53
18	Carboplatin: an active drug in metastatic breast cancer. 1992 ·Journal of Clinical Oncology ·Miguel Martín, Eduardo Díaz‐Rubio, Antonio Casado, P. Santabárbara, José Manuel López Vega, Encarna Adrover, Luigi Lenaz	61
19	Combination Chemotherapy with Oral Etoposide plus Intravenous Cyclophosphamide in Liver Metastases of Breast Cancer 1990 ·American Journal of Clinical Oncology ·Jordi Vilà, (unknown), (unknown), P. Santabárbara, (unknown), Santiago Gardella	6
20	Sudden Hearing Loss in an Adolescent following a Single Dose of Cisplatin 1988 ·ORL ·J. Doménech, P. Santabárbara, M. Carulla, J Traserra	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact